Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.
Brief Summary: An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints, quality of life and patient treatment satisfaction.

Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary).

Patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.


Options:
A: Inclusion Criteria:

* Symptoms of OAB (frequency more than 8 per day and Urgency more than 1 episode per day confirmed by bladder diary)

Exclusion Criteria:

* Significant hepatic or renal disease, history of radiation treatment
B: Inclusion Criteria:

* Voiding and storage symptoms diagnosed as LUTS associated with BPH for ≥ 3 months
* A total International Prostate Symptom Score (IPSS) of ≥13
* A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with voided volume of ≥120 mL during free flow
* A micturition frequency of ≥8 and at least 2 episodes of urgency with Patient Perception of the Intensity of Urgency Scale grade 3 or 4 per day on average on the 3 day micturition diary (at randomization)

Exclusion Criteria:

* Any significant Post Void Residual volume (\>150 mL)
* A prostate with estimated weight ≥75 ml as assessed by transvesical or transrectal ultrasound
* Evidence of a symptomatic urinary tract infection
C: Inclusion Criteria:

* Diagnosed with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
* BOO indication by a Bladder Outlet Obstruction Index (BOOI) ≥ 20
* Patient has a total International Prostate Symptom Score (IPPS) score of ≥ 8 (Inclusion criteria for Baseline also)
* Patient had a maximum urinary flow rate of ≤ 12 mL/sec, with a voided volume of ≥ 120 mL during free flow in a representative assessment of uroflowmetry.

Exclusion Criteria:

* History of urinary retention in preceding 12 months
* Current urinary tract infection (UTI) or symptomatic and recurrent UTI of \> 3 episodes within 12 months.
* Known clinical history or diagnosis of chronic inflammation, stone in bladder or ureter, or other causes of outflow tract obstruction
* Known diagnosis or history of carcinoma or previous pelvic radiation therapy, except non-metastatic basal or squamous cell carcinoma of the skin that had been treated successfully
* Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to Visit 1
D: Inclusion Criteria:

* male patients with LUTS associated with BPH diagnosed \> 3 months
* IPSS score \> 13
* voiding and storage symptoms
* maximum flow rate of \> 4 mL/s and \< 15 mL/s

Exclusion Criteria:

* post void residual volume \> 200 mL
* symptomatic urinary tract infection

Answer: A